The FDA-approved system is designed for providing moderate sedation to patients undergoing select gastrointestinal procedures, such as screening colonoscopy or EGD.
“It really allows us to use propofol, which we believe is superior to midazolam and fentanyl, in outpatients without having the added cost of having anesthesiologists administer [the drug],” said gastroenterologist Otto Lin, MD, according to the report.
More articles on gastroenterology:
The biggest threats to success in the GI field
9 GI physicians earning honors
6 GI physicians in the news
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.